According to The Insight Partners new market research study titled Chronic Cough Market Global Analysis and forecast by Drug Class, Route of Administration, and Distribution Channel, the global chronic cough market is expected to reachUS$ 9,854.8 million by 2027 from US$ 5,430.0 million in 2019; it is estimated to grow at a CAGR of 7.8% from 2020 to 2027. The report highlights the trends prevalent in the global chronic cough market, and the drivers and deterrents pertaining to its growth.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00011584/
Chronic cough is caused due to asthma, acid reflux from the stomach,and postnasal drip. The conditions such as infection, bronchitis, and lung diseases are also likely to lead to chronic cough. The condition such as asthma is rising across the world; it is commonly seen among children and adults. Itis a major cause of the growing health burden in the US. For instance,according to the Centers for Disease Control and Prevention (CDC) data published in 2019, one among every three people has asthma in the US. Across America, over 25 million people live with asthma, which accounts for ~8% in adults, and nearly 8.5% in children.
Based on drug class, the chronic cough market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and others drug class. The combination drug segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR in the market during the forecast period. The growth of the market through combination drug segment is estimated to grow due to enhanced sales of combination drugs over the counter and the use of combination drugs targets more symptoms in a single use.
In developing regions such as the Asia Pacific and the Middle East and Africa, the prevalence of chronic diseases is rising due to pollution and infections. The countries in these regions are highly populated. Although,cough is a non-communicable disease, it is increasing significantly in the countries. Several governments are putting their efforts to control the incidences of chronic cough in the respective countries. According to the National Health Policy 2017, India, premature mortality due to non-communicable diseases, including chronic cough, will be reduced by ~ 25% by 2025.
Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00011584
The growth of the market is attributed to the factors such as increase in rising incidences of chronic cough and growing product developments to treat chronic cough. On the other hand, product recall is the major factor likely to restraint the market growth during the forecast period.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Glaxo SmithKline plc.
- Bayer AG,
- Mylan N.V.
- Amneal Pharmaceuticals, Inc.
- Cipla Inc.
- Reckitt Benckiser Group plc
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Ltd
In the Middle East and Africa, respiratory diseases are rising due to climatic conditions. The countries surrounded by desserts are prone to the risk of respiratory diseases due to the easy spread of allergens. Over 60 to 70% of patients in the countries are diagnosed with respiratory diseases. Another major cause of chronic cough among people in the region is smoking. Nearly 30%of the people are addicted to smoking, which further leads to rising incidences of chronic cough.
Based on rout of administration, the chronic cough market is segmented into oral, injections, inhalation, and other route of administration. The oral segment held the largest share of the market in 2019. However, the inhalation segment is estimated to register the highest CAGR in the market during the forecast period.
Get a Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00011584/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.
Contact Person : Sameer Joshi .
Phone : +1-646-491-9876
E-mail : email@example.com